Ultragenyx board director Lars Ekman to retire after 2023 annual meeting

Ultragenyx Pharmaceutical Inc.

Lars Ekman, M.D., Ph.D. will retire from the Board effective immediately after the 2023 Annual Meeting on June 7, 2023.
Retirement is for personal reasons and not related to any disagreement with the Company or management.
No replacement director has been announced as of the filing date.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Lars Ekman

Director

RARE · Ultragenyx Pharmaceutical Inc.

Effective: 2023-06-07
Filed: March 23, 2023, 7:59 PM ET

On March 20, 2023, Lars Ekman, M.D., Ph.D. notified Ultragenyx Pharmaceutical Inc. (the “ Company ”) of his decision to retire from the Board of Directors of the Company (the “ Board ”), effective immediately after the Company’s 2023 Annual Meeting of Stockholders, currently scheduled for June 7, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Lars Ekman retired as Director at Ultragenyx Pharmaceutical Inc..

Action: retired
Role: Director

Exact text from the filing

On March 20, 2023, Lars Ekman, M.D., Ph.D. notified Ultragenyx Pharmaceutical Inc. (the “ Company ”) of his decision to retire from the Board of Directors of the Company (the “ Board ”), effective immediately after the Company’s 2023 Annual Meeting of Stockholders, currently scheduled for June 7, 2023.

View on SEC.gov

Ultragenyx Pharmaceutical Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-009543

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.